Aripiprazole and trazodone cause elevations of 7-dehydrocholesterol in the absence of Smith-Lemli-Opitz Syndrome

Molecular Genetics and Metabolism

Volumn 110, Issue 1-2, 2013, Pages 176-178

  Hall, Patricia ^a   Michels, Virginia ^a   Gavrilov, Dimitar ^a   Matern, Dietrich ^a   Oglesbee, Devin ^a   Raymond, Kimiyo ^a   Rinaldo, Piero ^a   Tortorelli, Silvia ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

7 dehydrocholesterol; Aripiprazole; Cholesterol; Smith Lemli Opitz Syndrome; Trazodone

Indexed keywords

7 DEHYDROCHOLESTEROL; ARIPIPRAZOLE; TRAZODONE; 7-DEHYDROCHOLESTEROL; 7-DEHYDROCHOLESTEROL REDUCTASE; OXIDOREDUCTASE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; DATA BASE; FALSE POSITIVE RESULT; HUMAN; MASS FRAGMENTOGRAPHY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING TEST; SMITH LEMLI OPITZ SYNDROME; BLOOD; GENETICS; MOLECULAR PATHOLOGY; MUTATION; PATHOLOGY;

DEHYDROCHOLESTEROLS; HUMANS; MUTATION; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PATHOLOGY, MOLECULAR; PIPERAZINES; QUINOLONES; SMITH-LEMLI-OPITZ SYNDROME; TRAZODONE;

EID: 84882926428     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.04.004     Document Type: Article

References (12)

1. DeBarber A.E., Eroglu Y., Merkens L.S., Pappu A.S., Steiner R.D. Smith-Lemli-Opitz syndrome. Expert Rev. Mol. Med. 2011, 13.
2. Tint G.S., Irons M., Elias E.R., Batta A.K., Frieden R., Chen T.S., Salen G. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N. Engl. J. Med. 1994, 330:107-113.
3. Kelley R.I., Hennekam R.C.M. Smith-Lemli-Opitz Syndrome. Metabolic and Molecular Bases of Inherited Disease 2001, McGraw Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
4. Diaz-Stransky A., Tierney E. Cognitive and behavioral aspects of Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 2012, 160:295-300.
5. Porter F.D. Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur. J. Hum. Genet. 2008, 16:535-541.
6. Kelley R.I. Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts. Clin. Chim. Acta 1995, 236:45-58.
7. Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin. Drug Metab. Toxicol. 2011, 7:829-846.
8. Preskorn S.H. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J. Clin. Psychiatry 1993, 54:14-34. (Suppl. discussion 55-16).
9. Wolf C., Chevy F., Pham J., Kolf-Clauw M., Citadelle D., Mulliez N., Roux C. Changes in serum sterols of rats treated with 7-dehydrocholesterol- δ 7-reductase inhibitors: Comparison to levels in humans with Smith-Lemli-Opitz syndrome. J. Lipid Res. 1996, 37:1325-1333.
10. Dehart D.B., Lanoue L., Tint G.S., Suli K.K. Pathogenesis of malformations in a rodent model for Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. 1997, 68:328-337.
11. Raeder M.B., Ferno J., Glambek M., Stansberg C., Steen V.M. Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci. Lett. 2006, 395:185-190.
12. Ferno J., Raeder M.B., Vik-Mo A.O., Skrede S., Glambek M., Tronstad K.J., Breilid H., Lovlie R., Berge R.K., Stansberg C., Steen V.M. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. Pharmacogenomics J. 2005, 5:298-304.